Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study

Launched by MỸ ĐỨC HOSPITAL · Feb 25, 2018

Keywords

ClinConnect Summary

A single center study pilot study in 30 IVF Bologna criteria POR patients. All patients fulfilling the ESHRE Bologna criteria will be eligible for inclusion.

Eight weeks prior to stimulation for IVF, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor daily will commence, concomitantly with GnRHa down-regulation with a depot GnRHa.

After 8 weeks, stimulation will be performed with a fixed dose of 300 IU rFSH (Gonal F, Merck) for the first 5 days in patients ≤ 34 years of age and 300 IU Pergoveris (Merck) in patie...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 - 41 years
• • BMI \< 30 kg/m2
• • Ovarian reserve, according to the ESHRE Bologna Criteria measured within two months prior to stimulation start
• Bologna criteria: At least two of the following three features present:
• • Advanced maternal age (≥40 years) or any other risk factor for POR
• • A previous POR (≤3 oocytes with a conventional stimulation protocol)
• • An abnormal ovarian reserve test (i.e. antral follicle count \< 5-7 follicles or AMH\< 0.5 - 1.1 ng/mL)
• • Poor responder if - Two previous episodes of POR after maximal stimulation (300 IU)
• • Receiving GnRH-antagonist co-treatment during ovarian stimulation
• • Agreement to participate in the study, and to disclose any medical events to the investigator. The subject must be willing and able to comply with the protocol requirements for the duration of the study.
• • Have given written informed consent with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
• Exclusion Criteria:
• • Chronical medical conditions like Diabetes, Crohns disease, Thyroid disease, Hepatitis B and Sexually Transmitted Diseases Simultaneous participation in an interventional clinical trial.